Humana AB (SE:HUM)
:HUM
Top Page
Humana AB
(HUM)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr50.00
▼(-0.79% Downside)
Action:DowngradedDate:02/08/26
The score is anchored by middling financial performance: weakening revenue/margins and higher leverage offset stable operations and generally decent cash conversion. Technicals are a meaningful drag due to a clear downtrend and negative momentum, while the low P/E and dividend yield provide a notable valuation cushion.
Positive Factors
Publicly funded, stable revenue streams
Humana's revenue is tied to public-sector reimbursements and contracted care delivery, creating predictable demand and payment collectability over time. That stable funding model reduces revenue volatility versus private-pay counterparts and supports planning across multi-year procurement cycles.
Negative Factors
High and rising leverage
Debt increased materially in 2025 and debt-to-equity rose, tilting the capital structure toward leverage. Elevated debt reduces financial flexibility, raises interest-service risk and limits ability to absorb reimbursement cuts or invest in capacity without refinancing, a lasting constraint on resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Publicly funded, stable revenue streams
Humana's revenue is tied to public-sector reimbursements and contracted care delivery, creating predictable demand and payment collectability over time. That stable funding model reduces revenue volatility versus private-pay counterparts and supports planning across multi-year procurement cycles.
Read all positive factors
Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr2.40B
Dividend Yield2.01%
Average Volume (3M)120.62K
Price to Earnings (P/E)10.6
Beta (1Y)0.66
Revenue Growth2.11%
EPS Growth92.69%
CountrySE
Employees11,127
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.57
Shares Outstanding51,826,057
10 Day Avg. Volume123,370
30 Day Avg. Volume120,620
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.81
Price to Sales (P/S)0.25
P/FCF Ratio3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.65
Revenue Forecast (FY)kr10.17B
Humana AB Business Overview & Revenue Model
Company Description
Humana AB (publ) provides individual and family care services for children and adults in Sweden, Finland, Norway, and Denmark. It operates through five segments: Individual & Family, Personal Assistance, Elderly Care, Finland, and Norway segments....
How the Company Makes Money
Humana AB primarily makes money by providing publicly funded social-care services and being reimbursed for delivering those services. Its key revenue streams typically include: (1) Personal assistance services, where Humana provides caregivers and...
Humana AB Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
45
Neutral
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.01B | 10.29B | 9.65B | 9.20B | 8.19B |
| Gross Profit | 831.00M | 896.00M | 757.00M | 9.14B | 8.13B |
| EBITDA | 1.11B | 1.05B | 908.00M | 901.00M | 892.00M |
| Net Income | 237.00M | 144.00M | 176.00M | 210.00M | 276.00M |
Balance Sheet | |||||
| Total Assets | 9.39B | 10.63B | 10.03B | 9.81B | 9.00B |
| Cash, Cash Equivalents and Short-Term Investments | 366.00M | 583.00M | 675.00M | 690.00M | 695.00M |
| Total Debt | 6.72B | 5.15B | 5.41B | 5.40B | 4.92B |
| Total Liabilities | 6.14B | 7.33B | 7.10B | 7.07B | 6.45B |
| Stockholders Equity | 3.12B | 3.16B | 2.89B | 2.74B | 2.55B |
Cash Flow | |||||
| Free Cash Flow | 666.00M | 570.00M | 451.00M | 442.00M | 582.00M |
| Operating Cash Flow | 770.00M | 869.00M | 621.00M | 633.00M | 689.00M |
| Investing Cash Flow | 172.00M | -532.00M | -151.00M | -246.00M | -260.00M |
| Financing Cash Flow | -1.13B | -434.00M | -457.00M | -424.00M | -521.00M |
Humana AB Technical Analysis
Positive
50.40
Price Trends
45.39
Positive
47.00
Negative
43.64
Positive
Market Momentum
0.74
Negative
53.03
Neutral
73.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Positive. The current price of 50.4 is above the 20-day moving average (MA) of 46.26, above the 50-day MA of 45.39, and above the 200-day MA of 43.64, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 53.03 is Neutral, neither overbought nor oversold. The STOCH value of 73.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HUM.
Humana AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | kr2.04B | 14.54 | ― | ― | 13.36% | -20.56% | |
65 Neutral | kr15.95B | 11.62 | ― | 1.47% | 2.96% | 73.50% | |
63 Neutral | kr10.73B | 17.78 | 12.96% | 1.56% | 10.83% | 16.24% | |
54 Neutral | kr1.65B | 54.90 | ― | ― | ― | ― | |
52 Neutral | kr2.40B | 10.62 | 7.53% | 2.01% | 2.11% | 92.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr1.27B | -7.05 | -35.03% | ― | ― | 25.14% |
* Healthcare Sector Average
SE:HUM
Humana AB
46.40
4.71
11.29%
SE:ATT
Attendo AB
105.80
48.03
83.13%
SE:AMBEA
Ambea AB
135.20
32.33
31.43%
SE:XSPRAY
Xspray Pharma AB
27.60
-1.34
-4.63%
SE:STIL
Stille AB
227.00
15.00
7.08%
SE:CARA
Carasent AB
24.05
1.84
8.26%
Humana AB Corporate Events
Humana sets May 7, 2026 AGM with expanded postal voting options
Mar 31, 2026
Humana AB has called its annual general meeting for May 7, 2026, in Stockholm, setting out how shareholders can participate either in person, by proxy or through postal voting. The notice details registration deadlines, procedures for nominee̴...
Humana Once Again Crowned Sweden’s Most Sustainable Healthcare Provider
Mar 12, 2026
Humana has been named Sweden’s most sustainable healthcare provider for the fourth time by the Sustainable Brand Index, underscoring its position as an industry leader that embeds sustainability into its business model. The recognition refle...
Humana to Double LSS Daily Activity Services with Homsan Acquisition
Mar 10, 2026
Humana has agreed to acquire Homsan AB, a Stockholm-region provider of daily activities under LSS, more than doubling Humana’s daily activity services and significantly expanding its local footprint. Homsan runs 13 units with around 200 part...
Humana Boosts Profitability, Cuts Debt and Lifts Dividend Despite Lower 2025 Revenue
Feb 6, 2026
Humana AB reported weaker fourth-quarter 2025 revenue of SEK 2,483 million, down 8% year-on-year, with organic growth at -1.9% and adjusted operating profit falling to SEK 87 million, while full-year net revenue slipped 3% but operating profit ros...
Humana AB Launches Share Buyback to Bolster Capital Structure and Acquisition Flexibility
Feb 6, 2026
Humana AB’s board has decided to repurchase up to 1,000,000 of the company’s own shares under a mandate from the 2025 annual general meeting, aiming to strengthen its capital structure and increase strategic flexibility for potential f...
Humana Completes Acquisition of Norwegian Care Provider Familiehjelpgruppen
Feb 2, 2026
Humana AB has completed the acquisition of Norwegian care provider Familiehjelpgruppen AS, following approval from the national Competition Authority. The deal significantly expands Humana’s preventive care and support services for children ...
Humana to Present Fourth-Quarter and Full-Year 2025 Results on 6 February
Jan 27, 2026
Humana AB has announced that it will publish its interim report for the fourth quarter and full year 2025 on 6 February 2025 at 08:00 CET, followed by a webcast and telephone conference at 09:00 CET where CEO and President Nathalie Boulas Nilsson ...
Humana Expands Elderly and LSS Care with New Central Sollentuna Facility
Jan 23, 2026
Humana has signed an agreement with property owner Knut Olsson Fastigheter AB to establish a new modern elderly care home with 100 beds and an LSS group home with six beds in central Sollentuna, just beside the municipal council hall and major pub...
Humana’s Nomination Committee Backs Full Board Re-Election and Continued Chairmanship
Jan 13, 2026
Humana’s Nomination Committee is proposing that the company’s Board of Directors for the 2026 financial year remains at seven members elected by the AGM, with all current directors – Grethe Aasved, Carolina Oscarius Dahl, Monica ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.